Ampio Pharmaceuticals logo
Ampio Pharmaceuticals AMPE
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Ampio Pharmaceuticals Financial Statements 2023-2008 | AMPE

Annual Financial Statements Ampio Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

664 K 188 K 6.64 M 296 M 78.4 M 46.2 M 145 M 46.9 M 111 M 283 M 273 M 132 M 100 M - - -

Shares

810 K 754 K 13.3 M 173 M 131 M 73.4 M 65.3 M 57.2 M 52 M 50.2 M 38.3 M 34 M 26 M 16.3 M - -

Historical Prices

0.82 0.25 0.5 1.71 0.6 0.63 2.22 0.82 2.13 5.64 7.12 3.88 3.86 - 355 -

Net Income

-8.63 M -16.3 M -17.1 M -15.9 M -13.6 M 34 M -51.9 M -19.2 M -32 M -38.1 M -24 M -11.6 M -18.4 M -8.05 M -1.51 M -

Revenue

- - - - - - - - 469 K 21.4 K 50 K 50 K 18.8 K - - -

Cost of Revenue

- - - - - - - - 244 K - - - - - - -

Gross Profit

- - - - - -523 K -568 K -950 K 793 K -2.16 M - - 18.8 K - - -

Operating Income

- - - - - - - - -33.3 M -39.1 M -24 M - - - - -

Interest Expense

- - - - - -5.01 K 3.09 K 3.69 K 11.5 K 22 K 29.3 K 29.3 K 8.36 K 19.5 K - -

EBITDA

122 K 1.05 M 1.09 M 1.18 M 1.27 M 1.28 M 1.21 M 1.21 M -32.5 M -38.7 M -23.9 M 62.4 K 42.6 K - - -

Operating Expenses

9.57 M 22.3 M 20.6 M 15.8 M 18.6 M 11.2 M 15.7 M 2.95 M 24.2 M 31.4 M 24.1 M 11.9 M 11.2 M 6.7 M - -

General and Administrative Expenses

7.08 M 11.5 M 8.67 M 6.66 M 5.95 M 4.36 M 5.26 M 6.54 M 9.06 M 8.96 M 1.7 M 1.4 M 4.5 M 4.73 M - -

All numbers in USD currency

Quarterly Income Statement Ampio Pharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

804 K 15.1 M 15.1 M 805 K 15.1 M 226 M 226 M 15.2 M 200 M 196 M 195 M 193 M 179 M 166 M 159 M 159 M 142 M 115 M 111 M 111 M 96.9 M 86.3 M 82.9 M 74.9 M 68.2 M 60.6 M 57.2 M 57.2 M 53.8 M 52 M 52 M 52 M 52 M 52 M 52 M 52 M 52 M 51.9 M 45 M 42.1 M 37.1 M 37.1 M 37.1 M 37 M 36.5 M 31.3 M 31.2 M 31.1 M 28.8 M 28.6 M 31.1 M

Net Income

-1.23 M -1.37 M -3.98 M - -6.41 M -2.07 M -5.64 M - -3.63 M -3.56 M -3.67 M - -3.37 M -2.73 M -5.18 M - -7.22 M 421 K -5.81 M - 5.8 M 4.62 M 22 M -43.1 M -4.25 M -2.61 M -1.9 M -3.35 M -3.99 M -5.05 M -6.76 M -10 M -7.37 M -7.36 M -7.28 M -9.91 M -9.49 M -8.93 M -10.5 M -7.34 M -6.19 M -6.59 M -4.21 M -3.68 M -2.58 M -2.5 M -2.84 M - -2.58 M -2.82 M -8.78 M

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -691 K -353 K 469 K 487 K 184 K 21.4 K 21.4 K - 21.4 K 12.5 K - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 244 K 37.3 K 87.9 K - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -7.67 M - - - -9.5 M - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - - - - - - - - - - -3.19 K - - - - 54 3.03 K 3.69 K 3.08 K 6.56 K 10.2 K 4.25 K -114 K 12.4 K 44.5 K 5.72 K 5.55 K 7.5 K 29.3 K 4.36 K 29.3 K 29.3 K 29.3 K - 29.3 K 29.3 K 29.3 K - 8.36 K 8.36 K 8.36 K

EBITDA

122 K 122 K 122 K - 865 K 518 K 262 K - 831 K 568 K 294 K - 885 K 591 K 295 K - 975 K 736 K 365 K - 968 K 621 K 301 K - 911 K 607 K 304 K - 917 K 611 K 306 K - -6.86 M 462 K 231 K - -9.29 M 83.1 K 41.2 K - 97.3 K 57.8 K 18.5 K - 46.8 K 31.2 K 15.6 K - 27 K 11.4 K -

Operating Expenses

1.4 M 1.56 M 4.4 M - 7.66 M 4.99 M 6.97 M - 3.85 M 3.67 M 3.82 M - 3.3 M 2.6 M 6.02 M - 5.17 M 3.58 M 2.68 M - 1.94 M 3.13 M 3.57 M 4.81 M 3.07 M 4.69 M 3 M 2.95 M 3.34 M 4.37 M 6.42 M 7.29 M 5.3 M 5.78 M 7.62 M 10.2 M 9.52 M 8.96 M 10.5 M 7.55 M 5.96 M 6.47 M 4.1 M 3.77 M 2.81 M 2.28 M 3.01 M - 2.78 M 1.58 M 2.24 M

General and Administrative Expenses

1.07 M 1.22 M 3.82 M - 2.98 M 3.24 M 3.28 M - 1.26 M 1.4 M 1.52 M - 1.65 M 1.48 M 1.77 M - 1.74 M 1.44 M 1.11 M - 756 K 1.01 M 1.52 M 1.37 M 1.07 M 1.34 M 1.36 M 1.31 M 1.56 M 1.56 M 2.11 M 2.87 M 3.41 M 4.01 M 609 K 2.94 M 555 K 662 K 2.07 M 2.46 M 1.15 M 1.22 M 1.31 M 1.44 M 678 K 727 K 1.54 M - 1.37 M 567 K 1.6 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Ampio Pharmaceuticals AMPE
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Ampio Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
- - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
- 0.38 % $ 12.9 M israelIsrael
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
- 2.07 % $ 34.4 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
- -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
- - $ 1.63 B usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA